Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Identification of Metabolic Function Derangements Such as Diabetes, Liver, Renal Issues by Respyr Smart Breath Analyzer and Its Validation as a Screening Tool Among Diseased and Healthy Controls

NCT07646015 is registered in ClinicalTrials.gov with Respyr as lead sponsor.

NCT NCT07646015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07646015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Identification of Metabolic Function Derangements Such as Diabetes, Liver, Renal Issues by Respyr Smart Breath Analyzer and Its Validation as a Screening Tool Among Diseased and Healthy Controls
Lead sponsor
Respyr
Phase
Observational
Overall status
Completed
Start date
October 3, 2022
Completion date
October 5, 2023
Enrollment
3,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, healthy volunteers, kidney diseases, liver diseases, lung diseases, metabolic diseases